- Registering at multiple transplant centers appears to give an edge to wealthy organ transplant patients over those with the most medical need.
- Multiple listing — more likely done by wealthy, privately insured patients — is an effective way to address organ shortages, but undermines the principle of transplanting the sickest patients first and should be reconsidered, researchers said.
Embargoed until 9 a.m. ET, Monday, Nov. 9, 2015
(NewMediaWire) - November 09, 2015 - ORLANDO, Florida - Registering with more than one organ transplant center appears to give an edge to wealthy patients over those with the most medical need, according to research presented at the American Heart Association’s Scientific Sessions 2015.
Researchers studied the national database of organ donors from 2000 to 2013 and found that patients who simultaneously listed at more than one center had higher transplant rates, lower death rates while waiting, were wealthier and were more likely to be insured.
“It’s an effective approach to address long waiting times and the shortage of organs available for the increasing demand among transplant candidates. But it undermines a bedrock principle of organ transplantation – which is that the sickest people should be transplanted first,” said Raymond Givens, M.D., Ph.D., study lead author and advanced heart failure and transplant fellow at Columbia University Medical Center in New York. “We firmly believe the multiple listing policy needs to be reconsidered.”
Researchers analyzed the United Network for Organ Sharing (UNOS) database, identifying adult patients listed as first-time, single-organ candidates for either heart, lung, liver or kidney transplants. The network is a nonprofit that manages the U.S. organ transplant system under federal contract. UNOS policy allows organ transplant candidates to be listed at multiple centers simultaneously.
Between 2000 through 2013, researchers identified: 33,928 patients waiting for a heart transplant (2 percent were multiple-listed); 24,633 patients waiting for a lung transplant (3.4 percent multiple-listed); 103,332 patients waiting for a liver transplant (6 percent multiple-listed); and 223,644 patients waiting for a kidney transplant (12 percent multiple-listed).
These findings suggest an advantage for wealthier patients who have the money for travel, temporary housing and other costs of multiple listing that are not covered by health insurance, Givens said. Patients with state-run Medicaid generally have lower income and may not have the option to list themselves at a center in a different state.
“The main issue is supply and demand,” Givens said. “The need for donor organs increases yearly; the supply does not. We really need more people to volunteer to donate their organs. That would relieve a lot of the strain on these inequalities. From a policy perspective, there is a need to redesign the system of organ allocation to ensure fairer access.”
Co-authors are Paul Christian Schulze, M.D., Ph.D. and Donna Mancini, M.D. Author disclosures are on the manuscript.
The International Society for Heart & Lung Transplantation and the Heart Failure Society of America funded the study.
Note: Actual presentation time is 2 p.m. ET, Monday, Nov. 9, 2015
- Available downloadable video/audio interviews, B-roll, animation and images related to this news release are on the right column of the release link at http://newsroom.heart.org/news/wealthiest-not-sickest-patients-may-have-edge-in-organ-transplants?preview=6e9ad9117b1225ead1161f1a5650a257
- Video clips with researchers/authors of the studies will be added to the release link after embargo.
- Heart Transplantation
- For more news from the AHA’s Scientific Sessions 2015 follow us on Twitter @HeartNews #AHA15.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
For Media Inquiries and AHA Spokesperson Perspective:
AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 7-11, 2015
at the Orange County Convention Center: (407) 685-5401
For Public Inquiries: (800) AHA-USA1 (242-8721)
Life is why, science is how . . .we help people live longer, healthier lives.